Joint MHRA/DIA Excellence in Pharmacovigilance

This course is designed to provide a firm grounding in key aspects of Global and mainly European Clinical Pre- and Post-Marketing Safety regulatory requirements. This five-day training course now also includes highlights and updates on the pharmacovigilance legislation and the latest news on the international harmonisation and standardisation activities in pharmacovigilance.

What participants from previous course say:
"Thank you for a great and comprehensive course. It was great to hear the perspectives of the different speakers as well as to meet a number of people working within this sector"
"A well organised course in an excellent location. The course director should be commended!"
"A very interesting course with lots of takeaway reading to do. The meeting was very well organised and the day schedule was kept to plan"

Who Should Attend
Professionals involved in pharmacovigilance and namely Qualified Persons for Pharmacovigilance (EU QPPV), clinical research, regulatory affairs, risk management, medical product safety assessment, and data analysis, epidemiology, labelling, quality assurance, compliance, medical information.

Level: Intermediate

Learning Objectives
For the five key topics as outlined above, the learning objectives also include the ability to:
Describe the main changes to the business processes in the context of the new pharmacovigilance legislation
Discuss the latest developments in the area of international harmonisation and standardisation with the main focus on the series of ICH E2 guidelines

URLs

Booking: http://atnd.it/28279-1

Price:
Member Charitable Nonprofit/Academia/Government: EUR 1630
Member Standard: EUR 3285
Charitable Nonprofit/Academia/Government: EUR 1790
Standard: EUR 3445

Speakers: Gaby L. Danan, Phil Tregunno, Jerome Calmejane

Time: On Monday September 28, 2015 at 8:00 am and ends Friday October 02, 2015 at 1:00 pm